IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Industrial Biotech

Crucell and DSM Hit Pharmaceutical Technology Milestone

10:51 AM MDT | June 16, 2008 | Alex Scott

Percivia, a biotech research business jointly owned by biotech firm Crucell (Leiden, the Netherlands) and DSM, says it has significantly raised the yield of its mammalian cell-based technology for producing therapeutic proteins. From the latest test results Percivia says its PER.C6 human cell line, in conjunction with XD Technology generated a record yield of more than 27 grams/liter of therapeutic proteins. The increase compares with a yield in March of this year of just 15 grams/liter. This milstone was achieved using standard bioreactor equipment and readily...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa